Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Beijing Biotech
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Stanford University
Mayo Clinic
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Intima Bioscience, Inc.
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
University Health Network, Toronto
University Health Network, Toronto
TCRCure Biopharma Ltd.
University of California, Irvine
Memorial Sloan Kettering Cancer Center
Hadassah Medical Organization
Valo Therapeutics Oy
TCR2 Therapeutics
TCR2 Therapeutics
Qingdao Sino-Cell Biomedicine Co., Ltd.
Memorial Sloan Kettering Cancer Center
University of Pittsburgh
Centre Hospitalier Universitaire Vaudois
M.D. Anderson Cancer Center
ImmunityBio, Inc.
ImmunityBio, Inc.
Immatics US, Inc.
Vall d'Hebron Institute of Oncology
Acepodia Biotech, Inc.
Adaptimmune
Essen Biotech
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
Gilead Sciences
Fate Therapeutics
Fate Therapeutics
Fate Therapeutics
Fred Hutchinson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Eastern Cooperative Oncology Group
Fate Therapeutics
Shanghai Zhongshan Hospital
BGI, China
University Health Network, Toronto
Incyte Corporation